Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical timolol for pediatric facial angiofibroma in tuberous sclerosis
IRCT20171230038142N18Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of timolol in facial angiofibroma and tuberous sclerosis complex (TSC), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Healing of skin lesions, Severity of facial angiofibroma and 1 more. Started Feb 2020; status: completed.
02
Drugs
timolol
03
Conditions
facial angiofibromatuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on IRCT20171230038142N18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171230038142N18.